BACKGROUND: There is a lack of prospective studies focusing on the sexual quality of life of prostate cancer patients after conformal radiotherapy (RT). OBJECTIVE: To evaluate the incidence, progression, and predictive factors for erectile dysfunction (ED). DESIGN, SETTING AND PARTICIPANTS: Patients who responded to the sexual domain of the Expanded Prostate Cancer Index Composite (EPIC) questionnaire before and more than 1 yr after RT and never received an antiandrogen treatment were included (n=123). INTERVENTION: RT dose was 70.2-72 Gy. Eleven patients used a phosphodiesterase-5 (PDE-5) inhibitor. MEASUREMENTS: Patients responded to the EPIC questionnaire before (time A), at the last day (B), a median time of 2 mo after (C), and 16 mo after (D) RT. In a multivariate analysis, risk factors (patient age, prostate volume, planning target volume, use of PDE-5 inhibitor, comorbidities) were tested for their independent effects on ED before and after RT. RESULTS AND LIMITATIONS: Sexual function and bother scores had already decreased by the end of RT (median function and bother scores at times A/B/C/D: 41/30/32/24 and 75/50/50/50). Initial function scores correlated well with late function scores (r=0.7; p<0.001). The ability to have an erection was reported by 81%/72%/74%/60% (preserved erectile ability in 70% at time D), erections firm enough for sexual intercourse by 44%/33%/35%/27% (preserved erections sufficient for intercourse in 53% at time D) of patients. A higher patient age and diabetes were predictive of both a pre-existing ED and a post-RT acquired ED. Nightly erections before treatment proved prognostically favourable (at least weekly vs. < weekly-hazard ratio of 5.9 for preserved erections sufficient for intercourse; p=0.01). Higher rates of ED can be expected with longer follow-up. CONCLUSIONS: The incidence of ED progressively increases after RT. Patient age and diabetes are risk factors for both pre-treatment and RT-associated ED. Nightly erections before RT proved prognostically favourable.
BACKGROUND: There is a lack of prospective studies focusing on the sexual quality of life of prostate cancerpatients after conformal radiotherapy (RT). OBJECTIVE: To evaluate the incidence, progression, and predictive factors for erectile dysfunction (ED). DESIGN, SETTING AND PARTICIPANTS: Patients who responded to the sexual domain of the Expanded Prostate Cancer Index Composite (EPIC) questionnaire before and more than 1 yr after RT and never received an antiandrogen treatment were included (n=123). INTERVENTION: RT dose was 70.2-72 Gy. Eleven patients used a phosphodiesterase-5 (PDE-5) inhibitor. MEASUREMENTS: Patients responded to the EPIC questionnaire before (time A), at the last day (B), a median time of 2 mo after (C), and 16 mo after (D) RT. In a multivariate analysis, risk factors (patient age, prostate volume, planning target volume, use of PDE-5 inhibitor, comorbidities) were tested for their independent effects on ED before and after RT. RESULTS AND LIMITATIONS: Sexual function and bother scores had already decreased by the end of RT (median function and bother scores at times A/B/C/D: 41/30/32/24 and 75/50/50/50). Initial function scores correlated well with late function scores (r=0.7; p<0.001). The ability to have an erection was reported by 81%/72%/74%/60% (preserved erectile ability in 70% at time D), erections firm enough for sexual intercourse by 44%/33%/35%/27% (preserved erections sufficient for intercourse in 53% at time D) of patients. A higher patient age and diabetes were predictive of both a pre-existing ED and a post-RT acquired ED. Nightly erections before treatment proved prognostically favourable (at least weekly vs. < weekly-hazard ratio of 5.9 for preserved erections sufficient for intercourse; p=0.01). Higher rates of ED can be expected with longer follow-up. CONCLUSIONS: The incidence of ED progressively increases after RT. Patient age and diabetes are risk factors for both pre-treatment and RT-associated ED. Nightly erections before RT proved prognostically favourable.
Authors: Melissa S Y Thong; Lonneke van de Poll-Franse; Richard M Hoffman; Peter C Albertsen; Ann S Hamilton; Janet L Stanford; David F Penson Journal: BJU Int Date: 2010-11-11 Impact factor: 5.588
Authors: Joseph M Herman; Amol K Narang; Kent A Griffith; Mark M Zalupski; Jennifer B Reese; Susan L Gearhart; Nolifer S Azad; June Chan; Leah Olsen; Jonathan E Efron; Theodore S Lawrence; Edgar Ben-Josef Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-09 Impact factor: 7.038
Authors: Mack Roach; Jiho Nam; Giovanna Gagliardi; Issam El Naqa; Joseph O Deasy; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Anne Holck Storås; Martin G Sanda; Montse Ferrer; Jon Håvard Loge; Alv A Dahl; Eivind A S Steinsvik; Ferran Guedea; Milada Cvancarova; Sophie D Fosså Journal: Clin Genitourin Cancer Date: 2014-01-03 Impact factor: 2.872
Authors: Michael Pinkawa; Richard Holy; Marc D Piroth; Karin Fischedick; Sandra Schaar; Dalma Székely-Orbán; Michael J Eble Journal: Radiat Oncol Date: 2010-04-08 Impact factor: 3.481
Authors: Michael Pinkawa; Marc D Piroth; Karin Fischedick; Sandra Nussen; Jens Klotz; Richard Holy; Michael J Eble Journal: Radiat Oncol Date: 2009-09-21 Impact factor: 3.481
Authors: Michael Pinkawa; Karin Fischedick; Bernd Gagel; Marc D Piroth; Branka Asadpour; Jens Klotz; Holger Borchers; Gerhard Jakse; Michael J Eble Journal: BMC Cancer Date: 2009-08-24 Impact factor: 4.430